Expertise in
23
conditions

Dr. Bruno S. Fang

Oncology
Titan Health Partners, LLC DBA Astera Cancer Care
629 Cranbury Road, Floor 2, 
East Brunswick, NJ 
Accepting New Patients
Offers Telehealth
Referral may be required
Expertise in
23
conditions
Titan Health Partners, LLC DBA Astera Cancer Care
629 Cranbury Road, Floor 2, 
East Brunswick, NJ 

Overview

Bruno Fang is an Oncologist practicing medicine in East Brunswick, New Jersey.

Dr. Fang is highly rated in 23 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Hodgkin Lymphoma, Pleuropulmonary Blastoma, and Small Cell Lung Cancer (SCLC).

Dr. Fang is board certified in American Board Of Internal Medicine and Internal Medicine. He is actively involved in clinical research, co-authoring 13 peer reviewed articles and participating in 12 clinical trials. Dr. Fang is currently accepting new patients.

Graduate Institution

Universidade De Sao Paulo Faculdade De Medicina

Specialties

Oncology

Licenses

Internal Medicine in NJ

Board Certifications

American Board Of Internal Medicine
Internal Medicine

Fellowships

National Institutes of Health

Hospital Affiliations

Community Medical Center
Ocean Medical Center
University Medical Center Of Princeton At Plainsboro
Saint Peter's University Hospital
Robert Wood Johnson University Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Clover Health
  • INSURANCE PLAN
  • MEDICARE MAPD
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health First
  • HMO
  • POS
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Nippon Life
  • INSURANCE PLAN
Oscar
  • EPO
  • HMO
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 18 Less Insurance Carriers -

Locations

Titan Health Partners, LLC DBA Astera Cancer Care
629 Cranbury Road, Floor 2, East Brunswick, NJ 8816.
Other Locations
Astera Medical Oncology Robbinsville
1 Washington Boulevard, Suite 9, Robbinsville, NJ 8691.
Astera Cancer Care
601 Route 37 West, Suite 9, Toms River, NJ 8755.
Astera Infusion Therapy East
629 Cranbury Rd, Fl 2, East Brunswick, NJ 08816

Additional Areas of Focus

Dr. Fang has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Metastatic Uveal Melanoma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

A Phase II Single-arm Trial to Investigate Tepotinib in Advanced (Locally Advanced or Metastatic) Non-small Cell Lung Cancer With METex14 Skipping Alterations or MET Amplification (VISION)
A Phase II Single-arm Trial to Investigate Tepotinib in Advanced (Locally Advanced or Metastatic) Non-small Cell Lung Cancer With METex14 Skipping Alterations or MET Amplification (VISION)
Enrollment Status: Active_not_recruiting
Publish Date: July 14, 2026
Intervention Type: Drug
Study Drug: Tepotinib
Study Phase: Phase 2
A Phase 1b/2, 2-part Open-label Study to Assess the Safety and Antitumor Activity of Zanidatamab in Combination With ALX148 in Advanced HER2-expressing Cancer
A Phase 1b/2, 2-part Open-label Study to Assess the Safety and Antitumor Activity of Zanidatamab in Combination With ALX148 in Advanced HER2-expressing Cancer
Enrollment Status: Completed
Publish Date: July 01, 2026
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
Phase 3, Open-Label, 4-Cohort Study of Nogapendekin Alfa Inbakicept in Combination With Current Standard of Care as First-Line Treatment for Patients With Advanced or Metastatic Non-Small Cell Lung Cancer
Phase 3, Open-Label, 4-Cohort Study of Nogapendekin Alfa Inbakicept in Combination With Current Standard of Care as First-Line Treatment for Patients With Advanced or Metastatic Non-Small Cell Lung Cancer
Enrollment Status: Terminated
Publish Date: May 26, 2026
Intervention Type: Drug
Study Drugs: N-803+Pembrolizumab, N-803+Carboplatin+Nab-paclitaxel+Pembrolizumab, N-803+Cisplatin or Carboplatin+Pembrolizumab+Pemetrexed, Pembrolizumab, Carboplatin+Nab-paclitaxel or Paclitaxel+Pembrolizumab, Cisplatin or Carboplatin+Pembrolizumab+Pemetrexed
Study Phase: Phase 3
Phase Ib Study of Gevokizumab in Combination With Standard of Care Anti-cancer Therapies in Patients With Metastatic Colorectal Cancer, Gastroesophageal Cancer and Renal Cell Carcinoma
Phase Ib Study of Gevokizumab in Combination With Standard of Care Anti-cancer Therapies in Patients With Metastatic Colorectal Cancer, Gastroesophageal Cancer and Renal Cell Carcinoma
Enrollment Status: Completed
Publish Date: April 01, 2026
Intervention Type: Drug
Study Drugs: Gevokizumab, Bevacizumab, Modified FOLFOX6, FOLFIRI, Ramucirumab, Paclitaxel, Cabozantinib
Study Phase: Phase 1
A Phase 2 Study of Magrolimab Combination Therapy in Patients With Unresectable, Locally Advanced or Metastatic Triple-Negative Breast Cancer
A Phase 2 Study of Magrolimab Combination Therapy in Patients With Unresectable, Locally Advanced or Metastatic Triple-Negative Breast Cancer
Enrollment Status: Terminated
Publish Date: November 04, 2025
Intervention Type: Drug
Study Drugs: Magrolimab, Nab-Paclitaxel, Paclitaxel, Sacituzumab govitecan
Study Phase: Phase 2
A Phase 2/3, Randomized, Open-Label Study of Maintenance GRT-C901/GRT-R902, A Neoantigen Vaccine, in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer
A Phase 2/3, Randomized, Open-Label Study of Maintenance GRT-C901/GRT-R902, A Neoantigen Vaccine, in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: May 16, 2025
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
An Open-label, Multi-center, ph II Platform Study Evaluating the Efficacy and Safety of NIS793 and Other New Investigational Drug Combinations With SOC Anti-cancer Therapy for the 2L Treatment of Metastatic Colorectal Cancer (mCRC)
An Open-label, Multi-center, ph II Platform Study Evaluating the Efficacy and Safety of NIS793 and Other New Investigational Drug Combinations With SOC Anti-cancer Therapy for the 2L Treatment of Metastatic Colorectal Cancer (mCRC)
Enrollment Status: Terminated
Publish Date: March 26, 2025
Intervention Type: Drug
Study Phase: Phase 2
VISION: An International, Prospective, Open Label, Multicenter, Randomized Phase 3 Study of 177Lu-PSMA-617 in the Treatment of Patients With Progressive PSMA-positive Metastatic Castration-resistant Prostate Cancer (mCRPC)
VISION: An International, Prospective, Open Label, Multicenter, Randomized Phase 3 Study of 177Lu-PSMA-617 in the Treatment of Patients With Progressive PSMA-positive Metastatic Castration-resistant Prostate Cancer (mCRPC)
Enrollment Status: Completed
Publish Date: January 13, 2025
Intervention Type: Drug, Other
Study Drug: 177Lu-PSMA-617
Study Phase: Phase 3
EPIK-B4: A Phase II, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Safety and Efficacy of Dapagliflozin + Metformin XR Versus Metformin XR During Treatment With Alpelisib (BYL719) in Combination With Fulvestrant in Participants With HR+, HER2-, Advanced Breast Cancer With a PIK3CA Mutation Following Progression on/After Endocrine-based Therapy
EPIK-B4: A Phase II, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Safety and Efficacy of Dapagliflozin + Metformin XR Versus Metformin XR During Treatment With Alpelisib (BYL719) in Combination With Fulvestrant in Participants With HR+, HER2-, Advanced Breast Cancer With a PIK3CA Mutation Following Progression on/After Endocrine-based Therapy
Enrollment Status: Terminated
Publish Date: October 09, 2024
Intervention Type: Drug
Study Drugs: Alpelisib, Fulvestrant, Metformin, Dapagliflozin
Study Phase: Phase 2
Randomized Crossover Ph3 to Evaluate Efficacy/Safety of Enobosarm Monotherapy vs Active Control for Treatment of AR+/ER+/HER2- MBC With AR Staining Previously Treated w/Nonsteroidal Aromatase Inhibitor, SERD & CDK 4/6 Inhibitor
Randomized Crossover Ph3 to Evaluate Efficacy/Safety of Enobosarm Monotherapy vs Active Control for Treatment of AR+/ER+/HER2- MBC With AR Staining Previously Treated w/Nonsteroidal Aromatase Inhibitor, SERD & CDK 4/6 Inhibitor
Enrollment Status: Terminated
Publish Date: January 26, 2024
Intervention Type: Drug
Study Drugs: Enobosarm, Exemestane
Study Phase: Phase 3
View 9 Less Clinical Trials

13 Total Publications

Ropeginterferon alfa-2b-njft treatment in essential thrombocythemia across different driver mutations: results from a North American, single-arm, multicentre study (EXCEED-ET).
Ropeginterferon alfa-2b-njft treatment in essential thrombocythemia across different driver mutations: results from a North American, single-arm, multicentre study (EXCEED-ET).
Journal: Lancet regional health. Americas
Published: March 25, 2026
Similar Doctors
Expertise in
26
conditions
Dr. Matthew J. Matasar
Hematology | Oncology
Expertise in
26
conditions
Dr. Matthew J. Matasar
Hematology | Oncology
Referral may be required

Rutgers Cancer Institute Of New Jersey

195 Little Albany St, 
New Brunswick, NJ 
 (5.0 miles away)
732-475-0824
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Matthew Matasar is a Hematologist and an Oncologist practicing medicine in New Brunswick, New Jersey. Dr. Matasar is highly rated in 26 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma, B-Cell Lymphoma, and Bone Marrow Transplant. Dr. Matasar is currently accepting new patients.

Expertise in
34
conditions
Dr. Steven M. Horwitz
Hematology | Oncology
Expertise in
34
conditions
Dr. Steven M. Horwitz
Hematology | Oncology
Referral may be required

David H. Koch Center For Cancer Care At Memorial Sloan Kettering Cancer Center

530 E 74th St, 
New York, NY 
 (33.9 miles away)
646-535-8986
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Steven Horwitz is a Hematologist and an Oncologist practicing medicine in New York, New York. Dr. Horwitz is highly rated in 34 conditions, according to our data. His clinical expertise encompasses Peripheral T-Cell Lymphoma, T-Cell Lymphoma, Non-Hodgkin Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Horwitz is currently accepting new patients.

Expertise in
13
conditions
Dr. Andrew M. Evens
Hematology | Oncology
Expertise in
13
conditions
Dr. Andrew M. Evens
Hematology | Oncology
Referral may be required

The Cancer Institute Of New Jersey

195 Little Albany St, 
New Brunswick, NJ 
 (5.0 miles away)
862-445-1542
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Andrew Evens is a Hematologist and an Oncologist practicing medicine in New Brunswick, New Jersey. Dr. Evens is highly rated in 13 conditions, according to our data. His clinical expertise encompasses Hodgkin Lymphoma, Classical Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Evens is currently accepting new patients.

Frequently Asked Questions about Dr. Bruno S. Fang

How do I make an appointment with Dr. Bruno S. Fang?

You can book an appointment with Dr. Bruno S. Fang by calling their office at 732-390-7750. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Bruno S. Fang a top-rated expert for Lung Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Bruno S. Fang is classified as an Distinguished expert for Lung Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Bruno S. Fang specialize in?

While Dr. Bruno S. Fang is a Oncology, they have specific expertise in Lung Cancer, Hodgkin Lymphoma, and Pleuropulmonary Blastoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Bruno S. Fang participate in research or clinical trials?

Yes. Dr. Bruno S. Fang has published 13 articles and abstracts on conditions like Lung Cancer. You can view a list of Dr. Bruno S. Fang's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Bruno S. Fang accept my insurance?

Dr. Bruno S. Fang accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 732-390-7750 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Fang's expertise for a condition
ConditionClose
    View All 19 Advanced Conditions
    View All 93 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile